Luc/GFP Reporter Cell Line-Raji

The researchers are making significant strides in immunotherapy for hematological malignancies, particularly with T cells engineered to express chimeric antigen receptors (CARs) targeting the CD19 antigen. This approach has demonstrated remarkable antitumor effects, achieving complete remission in patients with B-cell malignancies. However, ongoing improvements to the CAR structure are necessary to enhance both safety and efficacy. A critical component of this process involves using lentiviral vectors (LVVs) for T cell transduction, which allows these engineered cells to specifically target tumor antigens. Recent studies comparing second and third-generation LVVs have shown that the latter significantly boosts transduction efficiency and enhances the cytotoxic capacity of CAR-CD19 T cells against B-cell leukemia, ultimately leading to reduced tumor burden in mouse models.

Figure 1. The researchers utilized bioluminescence imaging to assess tumor suppression and survival rates in mice treated with CAR-CD19 T cells and engrafted with Raji cells. (Sawaisorn P, et al., 2023)

The Luc/GFP Reporter Cell Line-Raji from Creative Biogene provides a valuable tool for researchers exploring similar therapeutic avenues. This cell line can be utilized to model B-cell malignancies and evaluate the efficacy of CAR-T cell therapies. By incorporating luciferase and GFP, it enables real-time monitoring of tumor growth and therapeutic responses.